18 July 2018

LSIPR 50 2018: The entrepreneurial bug

Since its founding in 2000, Flagship Pioneering has set up and fostered the development of more than 100 scientific ventures, resulting in $20 billion in aggregate value, more than 500 issued patents, and more than 50 clinical trials for novel therapeutic agents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Dykema’s new trademark pro will be a ‘tremendous asset’ to clients

4 November 2026 Joining in Wisconsin, the senior counsel brings “sophisticated” trademark experience and leadership, and counts biotechnology among her sectors.

In-house counsel

In-house counsel rethink patent filing strategies as costs mount

3 November 2026 With budgets under pressure, counsel from Pfizer, ALX Oncology and BioMarin share how they are reassessing portfolios, trimming costs and prioritising key markets at LSPN Fall.

Careers

Fenwick hires NY partner to advise on regulatory matters

2 November 2026 New partner joins from Goodwin, where he was a life sciences partner, bringing experience in healthcare transactions, and regulatory and strategic counselling, among other areas.

More features

Dykema’s new trademark pro will be a ‘tremendous asset’ to clients

In-house counsel rethink patent filing strategies as costs mount

Fenwick hires NY partner to advise on regulatory matters

UK unveils £1bn sector investment push after recent setbacks

Oura targets Ultrahuman’s redesigned smart ring following import ban

Weil collapse leaves IP talent facing uncertain future after major expansion

Meril turns the tables on Edwards with European patent revocation

Regeneron and Amgen call a truce on two Eylea biosimilar patents

LSIPR 50 2018: The entrepreneurial bug

More on this story

Editor's picks

Editor's picks

More features